Medtronic's MiniMed Exchange Offer Oversubscribed at 18.3% Acceptance
MDT sits 24% above its 52-week low of $73.31 on light trading volume (0.2× avg).
Summary
Medtronic's exchange offer for its MiniMed Group split-off was oversubscribed, with an 18.3% acceptance rate. The offer, launched September 14, allowed shareholders to exchange Medtronic shares for MiniMed shares at a final ratio of 4.5939x, confirmed on October 7. Oversubscription indicates strong demand for the MiniMed stake, and the 18.3% acceptance rate reflects the proportion of Medtronic shares tendered. Medtronic will accept 55,032,401 tendered shares for 252,813,348 MiniMed shares, with a final proration factor expected October 14. The exchange offer expired at 12:00 midnight, New York City time, on October 9, 2026, and 298,024,452 Medtronic ordinary shares were validly tendered. Odd-lot shareholders are not subject to proration, and the 18.3% proration factor is preliminary and subject to change based on guaranteed delivery procedures. MiniMed's ticker symbol is MMED and it is listed on Nasdaq. The split-off is part of Medtronic's strategy to separate its diabetes business, and the oversubscription may lead to a proration of tendered shares.
Updated with an SEC 425 filing · What changed
Updates
· SEC 425 — Final proration factor set at 18.289133%; 297,521,390 shares validly tendered, 55,032,401 accepted.
- 296,763,500 shares tendered will be subject to proration.
- The exchange agent for the offer is Equiniti Trust Company, LLC.
- Odd-lot shareholders are exempt from proration only if they validly tendered all of their shares.
· SEC 425 — Medtronic will accept 55,032,401 tendered shares for 252,813,348 MiniMed shares; final proration factor expected October 14.
- Tender Results — 298,024,452 Medtronic ordinary shares were validly tendered, including 93,311,404 by notice of guaranteed delivery and 757,890 by odd-lot shareholders.
- Proration — Odd-lot shareholders (fewer than 100 shares) are not subject to proration. The 18.3% proration factor is preliminary and subject to change based on guaranteed delivery procedures.
- Post-Offer — Medtronic ordinary shares not accepted will be returned in book-entry form. Medtronic will not retain any outstanding shares of MiniMed common stock after the offer.
- Dealer Managers — Goldman Sachs & Co. LLC and BofA Securities, Inc. are the dealer managers for the exchange offer.
All 10 details
- MiniMed's ticker symbol is MMED and it is listed on Nasdaq.
- The exchange offer expired at 12:00 midnight, New York City time, on October 9, 2026.
- 298,024,452 Medtronic ordinary shares were validly tendered.
- 93,311,404 shares were tendered by notice of guaranteed delivery.
- 757,890 shares were tendered by odd-lot shareholders.
- Odd-lot shareholders (fewer than 100 shares) are not subject to proration.
- The 18.3% proration factor is preliminary and subject to change based on guaranteed delivery procedures.
- Medtronic ordinary shares not accepted will be returned in book-entry form.
- Medtronic will not retain any outstanding shares of MiniMed common stock after the offer.
- Goldman Sachs & Co. LLC and BofA Securities, Inc. are the dealer managers for the exchange offer.
At the time of this announcement, MDT was trading at $90.76 on NYSE in the Life Sciences sector, with a market capitalization of approximately $116.8B. The 52-week trading range was $73.31 to $106.33. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Seeking Alpha.